Andrea Sotak

Head of Strategy and SVP Corporate Development, Weatherden

Andrea Sotak is a life sciences strategic advisor, investor and corporate development leader, with a
20+ year track record of assessing what an asset is worth, and a detailed understanding of what drives
value in biopharma. Andrea has worked across all modalities, therapeutic areas, and stages of clinical
development. She currently serves as Head of Strategy & SVP Corporate Development at Weatherden, a UK-based firm that advises and supports companies by reducing strategic, technical and execution risk in drug development. Working with seed to mid-size biotech companies, VCs, and investors, she advises on matters ranging from corporate strategy and portfolio management to due diligence for acquisitions and partnerships. Andrea is also responsible for building and scaling Weatherden’s presence in North America.

From 2003 to 2019, Andrea served in various roles at DRI Capital, ultimately serving as President and Chief Investment Officer. She led the Investment team, established and oversaw the Investor Relations and Operations functions, and co-led all fundraising and financial activities, tripling the size of the organization and deploying over $1.9B into the acquisition of 60 pharmaceutical royalty streams.

Ms. Sotak began her career in life sciences at Allelix Biopharmaceuticals Inc. and spent several years working at Aventis Pasteur where she was instrumental in the launch of a vaccine production facility. She earned an MBA from Queen’s University and a Bachelor of Science in Biochemistry from the University of Waterloo.